McKellar Q A, Coop R L, Jackson F
Department of Veterinary Pharmacology, University of Glasgow Veterinary School, Bearsden, U.K.
Int J Parasitol. 1995 Oct;25(10):1207-12. doi: 10.1016/0020-7519(95)00053-5.
The principal metabolites detected in plasma of sheep following oral administration of albendazole (ABZ), albendazole sulfoxide (ABSO) and netobimin (NTB) each at 5.0 mg kg-1 body weight were ABSO and albendazole sulfone (ABSO2). The areas under the plasma concentration-time curve (AUC) for ABSO and ABSO2 were significantly (P < 0.05) larger following administration for ABSO than NTB in 1-month- and 8-month-old sheep. The AUC for the ABSO and ABSO2 metabolites were larger following administration of ABZ than NTB in 1-month- but not 8-month-old sheep and the AUC of the ABSO and ABSO2 metabolites were greater following ABSO than ABZ as parent compound in 8-month-old sheep only. The larger AUC values for metabolites following administration of ABSO as the parent compound were generally coincident with significantly higher maximum (Cmax) concentrations and not with persistence in the body, since mean residence times (MRT) of the metabolites were not significantly different from those determined following ABZ and NTB as parent compounds. The lower metabolite concentration following administration of NTB may have been a feature of its requirement for metabolic conversion and its larger molecular weight. Correction of AUC values for molecular weight removed any significant differences between AUC values for either metabolite in 8-month-old lambs. The corrected metabolite AUCs following NTB were, however, significantly lower than those following ABSO administration in 1-month-old lambs, suggesting that immature metabolic processes in these animals contributed to the lower relative bioavailability of NTB in this age group. Age did not affect the disposition of metabolites following ABZ or ABSO but the AUC of the ABSO metabolite following NTB was significantly (P = 0.014) lower in 1-month- than in 8-month-old sheep.
给绵羊按5.0毫克/千克体重口服阿苯达唑(ABZ)、阿苯达唑亚砜(ABSO)和奈托比敏(NTB)后,在其血浆中检测到的主要代谢物为ABSO和阿苯达唑砜(ABSO2)。在1月龄和8月龄绵羊中,给予ABSO后,ABSO和ABSO2的血浆浓度-时间曲线下面积(AUC)显著(P < 0.05)大于给予NTB后的。在1月龄而非8月龄绵羊中,给予ABZ后ABSO和ABSO2代谢物的AUC大于给予NTB后的;仅在8月龄绵羊中,以ABSO作为母体化合物时,ABSO和ABSO2代谢物的AUC大于以ABZ作为母体化合物时的。以ABSO作为母体化合物给药后,代谢物的AUC值较大,这通常与显著更高的最大(Cmax)浓度一致,而非与在体内的持久性一致,因为代谢物的平均驻留时间(MRT)与以ABZ和NTB作为母体化合物时测定的无显著差异。给予NTB后代谢物浓度较低可能是其需要代谢转化以及分子量较大的一个特征。对分子量进行AUC值校正后,8月龄羔羊中任一代谢物的AUC值之间不再有显著差异。然而,在1月龄羔羊中,NTB给药后校正后的代谢物AUC显著低于ABSO给药后的,这表明这些动物不成熟的代谢过程导致了该年龄组中NTB相对生物利用度较低。年龄不影响ABZ或ABSO给药后代谢物的处置,但NTB给药后ABSO代谢物的AUC在1月龄绵羊中显著(P = 0.014)低于8月龄绵羊中的。